In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.
Cambrex, a contract manufacture of small-molecule active pharmaceutical ingredients, is the latest contract manufacturer to establish an end-to-end-business model with its pending $425-million acquisition of Halo Pharmaceuticals, a CDMO of oral...
Emerging pharma companies are an important source of product innovation for the pharmaceutical industry, so which companies are making the mark? DCAT Value Chain Insights takes an inside look.
For new molecular entities approved by the US Food and...
The Pharmaceutical Research and Manufacturers of America (PhRMA) has released a new policy position that delinks supply-chain payments as a means to improve patient affordability. The policy is in response to an earlier blueprint issued by the US...
Strategic partnerships are key in delivering value in supply management, so what are some ways in which companies are collaborating to achieve such value?
DCAT Sharp Sourcing, which was held in New Brunswick, New Jersey in late June, featured...
Pfizer announced last week that it will reorganize into three businesses, an Innovative Medicines business, an Established Medicines unit, and a Consumer Healthcare business. So what is the restructuring all about?
This is the second...
A recent European Medicines Agency (EMA) survey shows that marketing authorization holders for more than half (58%) of the 694 centrally authorized products in the UK are on track with their regulatory planning to ensure that their marketing...
As we reach the mid-point of 2018, how are approvals of new molecular entities faring? As of the end of June, the FDA had approved 20 NMEs, a similar number as approved this time last year when the FDA had approved 23 NMEs by mid-year with an...
So which mergers and acquisitions among pharmaceutical companies have made the mark thus far in 2018? DCAT Value Chain Insights takes an inside look.
Two $60-billlion deals top the list. First is Bayer’s $63-billion acquisition of Monsanto, an...
Demand for capacity has driven the market for contract development and manufacturing (CDMO) services, but capacity alone will not be enough in the near term.
CDMO strategies need to look beyond today’s opportunities and brace for changing market...
Bayer’s completion of its $63-billion acquisition of Monsanto, an agrochemical and seed company, fortifies the company’s plan of becoming a pure-play life-sciences company focused on pharmaceuticals, crop science, consumer healthcare, and animal...
